Boothbay Fund Management LLC Invests $435,000 in Inhibrx, Inc. (NASDAQ:INBX)

Boothbay Fund Management LLC acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 28,230 shares of the company's stock, valued at approximately $435,000. Boothbay Fund Management LLC owned approximately 0.19% of Inhibrx at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. PNC Financial Services Group Inc. bought a new position in shares of Inhibrx in the fourth quarter worth $28,000. Natixis purchased a new position in shares of Inhibrx during the fourth quarter valued at about $31,000. JPMorgan Chase & Co. lifted its position in Inhibrx by 47.8% during the fourth quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock valued at $117,000 after purchasing an additional 2,457 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Inhibrx during the fourth quarter valued at about $47,000. Finally, New York State Common Retirement Fund purchased a new stake in Inhibrx during the fourth quarter valued at approximately $53,000. Institutional investors own 82.46% of the company's stock.

Inhibrx Price Performance

Shares of INBX traded down $0.38 during trading hours on Wednesday, reaching $12.06. 2,252 shares of the company traded hands, compared to its average volume of 192,339. The business has a fifty day moving average price of $12.96 and a 200-day moving average price of $13.89. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $34.75.

Inhibrx (NASDAQ:INBX - Get Free Report) last announced its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The business had revenue of $0.10 million for the quarter. On average, equities research analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.